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 PART – I 
VISUAL OUTCOME IN PATIENTS WITH PRIMARY 
IDIOPATHIC INTRACRANIAL HYPERTENSION 
INTRODUCTION 
PRIMARY IDIOPATHIC INTRACRANIAL HYPERTENSION 
commonly known as pseudo tumour cerebri or benign intracranial 
hypertension is a condition of unknown cause characterised by elevated CSF 
pressure and papilledema1.The diagnosis is established based on modified 
Dandy criteria. Its incidence is at least 0.9 to 1 per 100000 in general 
population, 1.6 to 3.5 per 100000 in women and increases to 7.9 to 20 per 
100000 in obese women of child bearing age2 .In children 1o IIH has equal 
sex incidence1. Visual loss caused by disc edema is the greatest morbidity of  
1° IIH, since10-25% of patients, including children, suffer serious visual 
loss3,4,7. 
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HISTORICAL REVIEW 
First report of 1° IIH was given by German physician HEINRICH 
QUINCKE in 1893 as serous meningitis5.MAX NONNE coined the term 
pseudotumour cerebri in the year 19046 . Diagnostic criteria for 1° IIH was 
developed by neurosurgeon WALTER DANDY in 1937. The term Otitic 
hydrocephalus was also used  for this disease since many patients had 
mastoiditis and venous thrombosis during the pre antibiotic era.6  
 “Benign intracranial hypertension” was the term coined by Foley and 
Weisberg.6 But this disease entity was associated with severe visual morbidity 
in around  10-25% of the cases and hence, it is not always benign. The name 
was therefore revised in 1989 by Corbett & Thomson as “IDIOPATHIC 
INTRACRANIAL HYPERTENSION” to emphasize the severity of the 
condition8. The  term “Idiopathic (primary) Intracranial Hypertension” is 
more appropriate and it is used nowadays. 
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REVIEW OF LITERATURE 
Study 1 
Long Term Visual Outcome in 1° IIH 
N.N.Baheti, M.Nair, S.V.Thomas 
Ann Indian Acad Neurol.2011 Jan. Mar; 14(1):19-22 
In this study  43 women with 1° IIH were included. Visual impairment 
was seen in 80 eyes (93%) at the time of diagnosis and it was moderate to 
severe in 14%. The patients with early severe visual impairment showed 
significantly higher [P=0.015] incidence of severe visual impairment during  
last follow up. Of the total 34 patients (79%) improved, 4 (9.3%)  patients 
showed relapse during  follow up after  a period of stability and 5 (11.6%) 
worsened over 56 months follow up. The conclusion of this study was  that 
there can be  delayed worsening or relapses  in1° IIH and about 10% patients 
can develop   visual loss permanently early or late in  course of disease. So,  
visual functions of 1° IIH  patients should be monitored  regularly over a long 
term period. 
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Study 2 
Clinical profile, evaluation, management and visual outcome of 1° IIH in 
a neuroophthalmology clinic of a tertiary referral ophthalmic center in 
India. 
S.Ambika, Deepak Arjundas, Veen Noronha 
Ann Indian Acad Neurol.2011 Jan. Mar; 13(1):37-41 
This was  a prospective study done on 50 patients diagnosed with 1° 
IIH.  Of those 50 patients, 40 were female patients and the average age was 
32.89 years [range 3½ to 49 yrs].The duration of follow up in these patients 
was 6 months. All 50 patients were  started on medical treatment ,  of which 
35 (70% patients) showed improvement of 2 lines in Snellen’s chart, disc 
edema had decreased ,field defects had improved and they were all in early to 
established stages of papilledema. The remaining 15 patients(30%) showed  
no clinical improvement even after 4 weeks and underwent CSF diversion 
procedures. Of these, 15 patients who underwent surgery , 7 patients showed 
improvement by 3-4 weeks, vision deteriorated in two patients and vision 
remained  same in rest of  patients. The conclusion of this study was that early 
onset (relatively good visual acuity, early disc edema, normal or minimal field 
defects) of medical treatment has prevented the patients from ending up with 
irreversible vision loss and optic atrophy. 
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Study 3 
Causes and prognosis of visual acuity loss at the time of initial 
presentation in 1° IIH. 
Chen JJ,Thurtell MJ, Longmuir RA, Garvin MK, Wang JK, Wall M, 
Kardon RH 
Invest ophthalmol vis sci.2015 jun:56(6):3850-9 
This is was a retrospective study conducted in 31 patients with 48 eyes 
having best corrected visual acuity of 20/25 or worse on initial presentation. 
Fundus photography ,OCT of the optic disc and macula and perimetry were 
used to determine the causes and prognosis of vision loss. Outer retinal 
changes alone caused decreased BCVA  in 22 eyes at initial 
presentation(46%): due to subretinal fuid in 16%,chorioretinal folds in 5% 
and peripapillary Choroidal neovascularisation in 1%.The vision loss was 
reversible except for some eyes with chorioretinal folds. Optic neuropathy 
alone caused decreased BCVA in 10 eyes(21%) and coexisting outer retinal 
changes and optic neuropathy caused decreased BCVA in 16 eyes(33%).A 
GCL-IPL thickness less than or equal to 70 micrometre at initial presentation 
or progressive thinning of greater than or equal to 10 micrometre within 2-3 
weeks compared with baseline correlated with  poor visual outcome. 
They concluded that visual acuity loss in 1° IIH can be caused by both 
outer retinal  changes  and optic neuropathy. Vision loss from outer retinal 
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changes is mostly reversible .The outcome of patients with coexisting  outer 
retinal changes and optic neuropathy or optic neuropathy alone depends on 
the degree of optic neuropathy, which can be predicted by the GCL-IPL 
thickness. 
 Study 4 
Assessment of visual function in patients with1° IIH: A Prospective 
study. 
Rowe FJ, Sarkies NJ. 
In this study ,visual function of 35 patients with 1° IIH was assessed 
propectively over a 3 year period .Number of tests including  visual field 
assessment with Humphrey and Goldmann perimeters and documentation of 
visual acuity and contrast sensitivity were done .Visual field assessment was 
documented as the most sensitive indicator of visual loss, with statistically 
greater sensitivity in comparison to visual acuity and contrast sensitivity 
testing. The types of visual field defects noted in this study were arcuate  
defects, nasal steps and global constriction. visual loss was noted at 
presentation and during follow up in upto 87% patients using Goldmann 
perimetry and upto 82% patients  using Humphrey perimetry. The visual 
status improved throughout the follow up period and the final visual outcome 
was excellent or good in 83% of patients.  
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Study 5 
Visual field defects in1° IIH 
Wall M, Hart WM Jr, Burde RM 
This was a retrospective study of 12 patients (all females, ranging in 
age from 6 to 44 years) using computerised visual field analysis. In seven of 
12 patients, the visual field loss appeared to be permanent, and follow up was 
too short for the final outcome to be determined into others. The visual field 
defects were blind spot enlargement in all 12 cases, isoptre constriction in 9 
cases and loss on the nasal side of the visual field in 7 cases, especially in the 
infero-nasal quadrant.4 patients had diminished visual acuities. The 
reversibility of visual field defects was co-related with the presence or 
absence of ophthalmoscopic signs of chronic papilledema. Because visual 
losses are reversible if treatment is begun before the onset of chronic 
papilledema, patients with 1° IIH should be monitored carefully with frequent 
perimetric and visual acuity testing.  
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Study 6 
Idiopathic Intracranial Hypertension: A prospective study of 50 patients.  
Brain.1991 Feb; 114:155-80 
The clinical status,  mainly visual function  was monitored in this study 
in 50 newly diagnosed 1° IIH patients. The follow up period was  2 to 39 
months .Patients with visual loss in Goldmann perimetry was  96% and in  
automated perimetry was  92%. Contrast sensitivity testing was  found to be 
abnormal in 50% and Snellen acuity  was abnormal in around  22% patients. 
Study 7 
 Sensory visual testing in idiopathic intracranial hypertension; measure 
sensitive to changes 
Wall M et al 
Neurology.1950 Dec; 40 (12): 1859-64 
This study used the results of 19 patients whose clinical status 
improved [decreased in papilledema grade] with treatment, and compared the 
outcome measures of the initial and final examinations. Contrast sensitivity 
testing showed significant improvement in the middle and high spatial 
frequency targets. Snellen acuity and colour test did not change significantly 
over the same period. Both Goldmann and automated visual field grade 
9 
 
significantly improved from the initial to final visit, while the presence of a 
defect on confrontation visual field did not. Thus, concluding that patients 
with 1° IIH should be followed with contrast sensitivity testing and perimetry 
using a disease specific strategy. 
Study 8 
The relationship between obesity and Idiopathic Intracranial 
Hypertension   
Rowe FJ, Sarkies NJ 
  This study included 34 patients with 1° IIH; 70.9% of these patients  
were obese. The relative risk for obesity & 1° IIH was at 8 [significant 
95%CI]. This increased to 17 [95%CI] for obese females aged 16 to 24 years 
and 10 [95% CI] for obese females aged 25 to 34 years. They concluded that a 
high degree of obesity correlated with a poor visual outcome and identified as 
a risk factor for severe visual deterioration. Obesity may be an etiological 
factor although it may not be the sole cause but more probably a precipitating 
factor. 
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Study 9 
Obesity may not be a risk factor for idiopathic intracranial hypertension 
in Asians 
Kapoor KG 
Eur J Neurol.2008 Aug; 15(8): 876 – 9 
Ten patients who fulfilled the modified Dandy criteria and four with 
presumed diagnosis for 1° IIH were studied. Only one patient was obese 
according to BMI , seven were overweight and six had normal weight. This 
study concluded that obesity was not commonly  found in Caucasians with 1° 
IIH and indirectly suggested that obesity may not play a major role in the 
pathogenesis of 1° IIH in Asians. 
11 
 
EPIDEMIOLOGY 
An obese woman of childbearing age is typically affected. Patients of 
any age can be affected with idiopathic intracranial hypertension. However 
most patients are in the third decade of their life.9 Women are most commonly 
affected and they account for about 92% of the 1° IIH cases.10However, men 
with idiopathic intracranial hypertension are twice as likely as women to lose 
visual function due to their papilledema .The incidence rate of1° IIH is found 
to be 0.9 to 1 per 100,000 in the general population  by an epidemiological 
study conducted  in Iowa and Lousiana. The incidence rises to 3.5 per 
100,000 in women aged 20-44 years. The incidence rate of 13-14.8/100,000 
was found in women who are 10% or more over the ideal weight. The 
incidence rate also increased to 19.3/100,000 for women who are more than 
20% of the ideal body weight. 2 The female-to-male ratio of this study was 
8:12.  
One  study conducted  in Libya showed  an incidence rate  of  about 
2.2 per 100,000 in  general population.11 The incidence rate was 4.3 per 
100,000 in women and 21.4 per 100,000 in women who are  20% over  
weight11.  Incidence rate  of 1° IIH differs  from country to country, because  
the prevalence of obesity in different parts of the world is  different. 
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IDIOPATHIC INTRACRANIAL HYPERTENSION 
MODIFIED DANDY CRITERIA FOR 1° IIH12 
1. Clinical features of increased ICP (headache, nausea, vomiting, 
transient obscuration  of vision, papilledema) 
2. Normal neurological examination, except for a sixth  nerve  
palsy/paresis. 
3. Raised  opening  CSF pressure (>250 mm H2O) with normal  CSF 
constituents. 
4.  Neuroimaging (CT, with and without contrast, or MRI) 
demonstrates normal or  small symmetric ventricles and absence of  
a mass lesion or other causes of raised ICP12. 
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PATHOPHYSIOLOGY 
 The normal  mechanisms that are mainly involved in maintenance of 
ICP are as follows: 
1. Compliance factor(that arises due to distension of meninges and 
vascular volume compression). 
2. Resistant factor (by which CSF pressure is modulated by venting 
CSF into the arachnoid granulations so that it enters the cerebral 
venous system).13 
 The resistance factors are quickly exceeded in the intracranial 
compartment. When CSF volume is raised, at one point the compliance 
mechanisms fail and even small increase in the csf volume can result in raised 
ICP.14  
The various mechanisms of raised ICP in 1° IIH are as follows: 
CSF hyper secretion 
In 1979 ventricular infusion studies (which monitor CSF dilution and 
calculate the rate of CSF production) demonstrated elevated CSF secretion in 
five patients with 1° IIH. Velocity sensitive magnetic resonance imaging 
(MRI), a calculation of CSF flow, showed hyper secretion in 1° IIH15. Though 
the observation that CSF protein levels are reduced in 1° IIH supports the 
theory of CSF hyper secretion16.Low protein in 1° IIH is not a universal 
finding17. Though a possible mechanism of overproduction of CSF has been 
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implicated in the etiology of1° IIH ,Studies indicate that there is no difference  
in CSF production in both1° IIH patients and control groups.18  
Increased CSF outflow resistance:  
The CSF is  mainly  drained through  arachnoid villi of   brain, but 
arachnoid granulations of spine also play some role. Impaired CSF drainage  
in 1° IIH patients is demonstrated by radioisotope cisternography and CSF 
infusion studies19. 
Increased cerebral venous pressure:  
There is considerable evidence from venography and manometry 
studies that venous sinus pressure is raised in 1° IIH, particularly in the 
transverse and superior sagittal sinuses20.Stenosis involving  the cerebral 
venous sinuses has been shown in cerebral venography suggesting  an outflow 
obstruction functionally in patients with 1° IIH, in  absence of thrombotic 
occlusion21. 
Obesity and1° IIH:  
Obesity is defined as a body mass index greater than 30 kg/m2 22. The 
incidence of 1° IIH increases to 19.3 to 21 per 100,000 in the obese 
population compared with 0.9 to 2.2 per 100,000 in the general population18. 
Obesity and its association with 1° IIH  has been confirmed in many studies 
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23, 25. Obesity of high degree (BMI >40 kg /m2) correlates with poor visual 
outcome24.  
Mechanisms of raised ICP in obesity:  
(1) Obstructive sleep apnoea, a condition associated with obesity,   
leads to nocturnal hypercapnia, right heart failure and surges in 
intrathoracic pressure which can elevate ICP26. 
(2) Pressure effects of centrally distributed adiposity; elevate intra-
abdominal pressure which subsequently elevates intra-thoracic 
pressure and cerebral venous pressure and finally ICP27.  
(3)Adipose tissue and its products, leptin and ghrelin, are found to 
have a possible role in 1° IIH. Leptin positively correlates with 
BMI28. There is  dysregulation of insulin, glucose metabolism, sex 
hormones, adipokines, glucocorticoids, lipids, and free fatty acids 
in obesity  and it  may predispose  to 1° IIH29. 
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SECONDARY CAUSES 
Although 1° IIH is primarily a disease of obese young females and 
occasionally obese males ,it can occur in non obese women, prepubertal 
children and men .In these  cases the secondary causes of increased ICP have 
to be ruled out .the secondary causes should also be ruled out in patients who 
present with rapid and severely progressive visual loss.23 
Obstruction or Impairment of Intracranial Venous Drainage23 : 
Obstruction of superior sagittal and transverse sinus  
Ø Primary hematologic  
Ø Activated protein C deficiency  
Ø Essential thrombocythemia  
Ø Factor V Leiden mutation  
Ø Idiopathic thrombocytopenic purpura 
Ø Paroxysomal  nocturnal hemoglobinuria 
Systemic conditions associated with coagulopathy  
Ø Behcet's disease  
Ø Pregnancy  
Ø Renal disease  
Ø Systemic lupus erythematosus 
Ø Neurosarcoidosis  
Ø Trichinosis  
17 
 
Surgical/traumatic  
Tumors  
Obstruction of transverse sinus 
Ø Dural arteriovenous fistula  
Ø Infection (mastoiditis)  
Ø Haematologic 
Ø Tumours (extra vascular) 
Occlusion of internal jugular vein  
Ø Iatrogenic  
Ø Indwelling catheter  
Ø Surgery/traumatic/tumour  
Endocrinologic and Metabolic Conditions:  
Ø Addison's disease  
Ø Hypoparathyroidism  
Ø Obesity (idiopathic)  
Ø Turner's syndrome  
Medications:  
Ø Amiodarone  
Ø Tetracycline 
Ø Minocycline  
Ø Doxycycline  
18 
 
Ø Nalidixic acid 
Ø Isotretinoin 
Ø Vitamin A 
Ø All –trans retinoic acid 
Ø Growth hormone 
Ø Lead 
Ø Leuprolide acetate 
Ø Levonorgestrel implants 
Ø Thyroid hormone 
Ø Corticosteroids withdrawal  
Ø Lithium 
Ø Oxytocin(intranasal) 
Ø Danazol administration or withdrawal  
Ø cyclosporine 
Systemic Illnesses:  
Ø Anaemia 
Ø Chronic respiratory insufficiency 
Ø Hyperthyroidism 
Ø Sarcoidosis 
Ø Thrombocytopenic purpura 
Ø Vitamin D deficiency 
Ø Renal disease 
Ø Obstructive sleep apnea 
19 
 
CLINICAL EVALUATION 
HISTORY 
Use of vitamin A or multi-vitamins in large quantities, the recent use 
of nalidixic acid, tetracycline, doxycycline, minocycline, or lithium, or the 
recent discontinuation of corticosteroids, even topical steroids should be 
noted30. 
HEADACHE 
 The  most common presenting  symptom in patients with 1° IIH is headache.. 
The headaches of 1° IIH vary in intensity from mild to severe. Pre-existent 
migraine may worsen with1° IIH. There is no clear correlation between the 
height of the CSF pressure and the severity of headache. The headache is 
characteristically worse while  awakening, it is throbbing in nature and 
associated symptoms like  photophobia or phonophobia can be 
present.Valsalva maneuver can exacerbate the headache30. 
TRANSIENT VISUAL OBSCURATIONS:  
Monocular or binocular transient visual obscuration’s (TVOs) are 
second most common symptoms. Blurring or total loss of vision lasts seconds, 
rarely longer, and is frequently precipitated by some change in posture or the 
Valsalva manoeuvre23.In some patients the frequency of TVO’s can vary from 
20 to 30 times per day. TVOs indicate the presence of optic disc edema and 
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are not in isolation, an ominous symptom if the vision returns to normal 
interictally. It indicates a  transient ischemia to the optic nerve head due to 
papilledema10.With severe disease; ischemic optic neuropathy ensues, 
producing rapid severe and irreversible visual loss31.  
DIPLOPIA: 
Diplopia, a less common symptom, is almost always horizontal, and 
caused by sixth nerve paresis. It is seen in 40 % of patients. It is a non 
localising feature of increased intra cranial pressure10. 
TINNITUS: 
Intracranial noises ( tinnitus that is pulsatile in nature),can be present in 
around  60% patients. It has a characteristic  whooshing sound  and they 
indicate  disturbances of blood flow  in  venous system of the brain32. They  
are unilateral or bilateral and most pronounced at night.  jugular compression 
ipsilateral to the side of tinnitus  results in  abolition of sound27. 
PERSISTENT VISUAL LOSS: 
When persistent loss of vision is the presenting complaint, permanent 
severe visual loss is common. The causes of permanent visual acuity loss in 
1° IIH include  
v optic disc infarction,  
v macular changes,  
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v sub retinal haemorrhage, and 
v a combination of ischemic and compressive damage to the optic 
nerves33, 34, 35, 36. 
FOCAL NEUROLOGICAL DEFICITS: 
Focal neurological deficits are extremely uncommon and alternate 
diagnosis has to be considered. Nevertheless, isolated facial paresis, hemi 
facial spasm, trigeminal sensory neuropathy, hearing loss, hemi paresis, 
ataxia, paresthesias, mononeuropathy multiplex, arthralgias, both spinal and 
radicular pain has been reported in patients with 1° IIH37. 
SIGNS 
PAPILLEDEMA: 
It is the diagnostic hallmark of 1° IIH 20.there is no correlation between 
visual loss and high grade papilledema, the appearance of disc does not 
predict visual loss. There is no correlation between severity of papilledema 
and age, race, body weight in patients with 1° IIH38. 
CLASSIFICATION OF PAPILLOEDEMA 39  : 
There are several classification systems for papilloedema. One system 
describes the disc appearance according to the 
 
 
 
STAGES  OF  PAPILLEDEMA IN PRIMARY 
IDIOPATHIC INTRACRANIAL 
HYPERTENSION    
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1. Duration of papilloedema:  
(a) Early;  
(b) Established 
(c) Chronic; and  
(d) Atrophic  
EARLY  PAPILLEDEMA 
· Symptoms are  absent usually in these patients 
· Vision is within  normal limits 
· Pupillary reactions are normal 
· Ophthalmic features include 
Ø Blurring  of disc margins (nasal margins are involved 
first followed by superior, inferior & temporal) 
Ø Blurring of peripapillary region  
Ø Absence of spontaneous venous pulsation at the disc. 
Ø Mild hyperaemia of the disc 
Ø Splinter haemorrhages in the peripapillary region can be 
present. 
Ø Visual fields show– Normal (or) Enlargement of blind 
spot(+) 39 
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ESTABLISHED (FULLY DEVELOPED) PAPILLEDEMA: 
· Symptoms: H/o. TVO’s on one (or) both eye may be present. 
· Vision is normal. 
· Pupillary reactions are fairly normal. 
· Ophthalmic features include 
Ø  Marked hyperaemia of the Disc  with blurring of all 
margins of the disc is noted. 
Ø Physiological cup of the disc is obliterated. 
Ø Multiple cotton wool spots and superficial haemorrhages 
can  be seen near the disc. 
Ø  Toruosity and engorgement  of the Veins noted. 
Ø In advanced cases, the disc appears to be enlarged and 
circumferential greyish white folds can  develop due to 
separation of nerve fibres by the edema.39 
Ø Rarely, hard exudates may be seen  radiating  from the 
fovea in the form of an incomplete star. 
Ø enlargement of blind spot in noted in the visual fields. 
CHRONIC  PAPILLEDEMA: 
· Symptoms: Visual acuity can be  variably reduced depending 
upon the duration of papilledema. 
· Pupillary reactions are usually normal. 
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· Ophthalmic features includes 
Ø Peripapillary edema is resorbed. 
Ø Acute haemorrhages and exudates resolve. 
Ø  Dome of champagne cork appearance of the Optic disc 
is noted. 
Ø Central cup becomes obliterated. 
Ø Corpora amylacea  which are Small drusen like 
crystalline deposits   can  appear on the disc surface. 
Ø  enlargement of blind spot  is noted and visual fields start 
to constrict.39 
ATROPHIC PAPILLEDEMA: 
·  atrophic papilledema occurs  after 6-9 months of chronic 
papilledema is associated with severely impaired visual acuity. 
· Pupillary reaction: Light reflex is impaired. 
· Ophthalmic features includes 
Ø Greyish white  pallor of the disc because of  atrophy of 
neurons and associated gliosis. 
Ø Disc edema is reduced . 
Ø  Narrowing of retinal arterioles noted and veins are less 
congested. 
Ø  sheathing develops around the vessels. 
Ø There is concentric contraction of peripheral fields. 39 
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2.  Frisen grading system39 is most useful as it classifies the papilloedema 
grade by severity  
Stage 0 Normal Optic Disc  
· Blurring of nasal, superior and inferior poles in inverse proportion to 
disc diameter.  
· Radial nerve fiber layer (NFL) without NFL tortuosity.  
· Rare obscuration of a major blood vessel, usually on the upperpole.  
Stage 1 Very Early Papilloedema  
· Obscuration of the nasal border of the disc.  
· No elevation of the disc borders.  
· Disruption of the normal RNFL arrangement with grayish opacity 
accentuating NFL bundles.  
· Normal temporal disc margin  
· Subtle grayish halo with temporal gap (best seen with indirect 
ophthalmoscopy) Concentric or radial retrochoroidal folds.  
Stage 2 Early Papilloedema  
· Obscuration of all borders.  
· Elevation of the nasal border  
· Complete peripapillary halo.  
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Stage 3 Moderate Papilloedema  
· Obscurations of all borders.  
· Increased diameter of optic nerve head.  
· Obscuration of one or more segments of major blood vessels leaving 
the disc.  
· Peripapillary halo-irregular outer fringe with finger-like extensions  
Stage 4 Marked Papilloedema  
· Elevation of the entire nerve head.  
· Obscuration of all borders.  
Post Papilledema Atrophy (Secondary Optic Atrophy): 
 With time, untreated papilledema subsides; the disc becomes atrophic, 
and narrowing of retinal vessels and sheathing can be noted. If the ICP rise is 
rapid, severe & sustained, atrophy can occur within weeks (or) even years 
may elapse before atrophy develops. Optic atrophy that results from 
papilledema follows a specific pattern of axonal loss. The  peripheral axons  
are lost  and there occurs a sparing of central axons with retained  good 
central visual acuity despite severe papilledema & optic atrophy is found in 
these patients. 
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Diagnosis of Papilloedema:  
The most important method of diagnosing papilloedema is careful 
ophthalmoscopic examination, assessing the features described above. An 
examination that includes  
• Red-free ophthalmoscopy  
• Indirect ophthalmoscopic examination  
• Slit lamp biomicroscopy using 90 D lens .  
• Fluorescein angiography : 
The  fluorescein angiogram in patients with early papilloedema shows  
dilation of capillaries over the disc, leakage of the dye and microaneurysm 
formation, whereas later stages leakage of dye beyond the disc margins is 
noted .  
• Orbital echography is extremely useful in cases of questionable 
papilloedema. This sensitive test reliably determines if the diameter of the 
optic nerve is increased and, if so, whether or not the increase is caused by 
CSF surrounding the nerve. It can also easily detect buried optic disc drusen. 
Thus,  A- and B-scan ultrasonography with a 30Â° test can be used to 
diagnose true edema of the disc along with increased ICP 40.  
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• CT scanning can be used to determine if there are buried drusen 
causing an appearance mimicking papilloedema, and both CT scanning and 
MR imaging can be used to detect evidence of an intracranial mass or 
hydrocephalus41. 
  High resolution MRI of the orbits shows characteristic changes of the 
optic nerves and posterior globe in papilloedema. In papilloedema,the 
subarachnoid space becomes distended, the nerve sheath widens, there is 
flattening of the posterior sclera . The prelaminar optic nerve may enhance 
and protrude anteriorly41. 
Confocal scanning laser tomography 
  Confocal scanning laser tomography (CSLT; Heidelberg Retinal 
Tomography) of normal optic nerves demonstrates gradually increasing 
retinal surface elevation from the center of the disc to the disc margin42.   
CSLT holds great promise as a reliable ,reproducible method to quantify the 
three dimensional topography of the optic nerve head77.      
Optical coherence tomography(OCT) 
It is  a non invasive imaging technique. The  retinal images  obtained 
in OCT resemble  histologic preparations and  hence it is useful for evaluating 
and monitoring  the peripapillary nerve fibre layer. It  can detect and quantify 
diffuse RNFL thickening  in eyes with optic disc edema associated with 
several neuropathies.78 
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OCT has spatial resolution of 10 nm or less.Several case series study 
have shown that OCT may be helpful in the detection,characterisation and 
monitoring of RNFL swelling in the event of optic disc edema in patients with 
1° IIH.78 
Differential Diagnosis of Papilledema: 
1. Anomalously elevated optic disc due to optic disc drusen 
2.  tilted optic disc, 
3.  hypoplastic optic disc. 
4. Intraocular inflammation 
5. Asymptomatic non arteritic anterior ischemic optic neuropathy (e.g: 
diabetic papillopathy) 
6. Hypertensive disc edema 
7. Optic neuritis 
8. Infiltrative optic neuropathy 
9. Compressive optic neuropathy.39 
Visual acuity: 
Visual acuity is remains normal during  the early stage of papilledema 
but  it can reduce very  suddenly and fastly  in  patients with severe or 
advanced stages. It is relatively insensitive to visual loss in 1° IIH and should 
not be relied upon as the sole indicator of visual function43. Colour vision 
testing and visual evoked potentials are similarly insensitive44. In general, 
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early central acuity loss, particularly if it is rapidly progressing, is a 
worrisome sign.  
RISK FACTORS FOR VISUAL LOSS4, 45-47 
Factors associated with  visual loss includes  
v  History of Recent weight gain  
v High-grade  of papilloedema  
v Atrophic papilloedema  
v  Presence of Subretinal hemorrhage  
v  Presence of Significant visual field loss at the time of 
diagnosis  
v Hypertension 45-47 
           Factors that are not associated with visual loss 4 
v Duration of symptoms  
v Transient visual obscurations  
v Diplopia  
v tinnitus 
v severity of headache  
v  CSF Opening pressure  
v Pregnancy  
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Factors independently associated with a worse visual outcome include 
v Gender(male) 
v Race(blacks) 
v Morbid obesity 
v Anemia 
v Obstructive sleep apnea 
v Fulminant IIH  
CONTRAST SENSITIVITY: 
In patients with 1° IIH, loss of contrast sensitivity is frequently found 
50. So, contrast sensitivity testing is recommended by the researchers as a 
adjunctive measure for assessing optic nerve function. Though this test can 
detect  abnormalities in the optic nerve function when other tests are found to 
be normal, its specificity is low 49. The Pelli-Robson test is a wall chart that 
measures 90 X 60 cm (36 X 24 inches).  In the chart there are  8 lines of 
letters and they have  different contrasts. There are  six letters in each line .  
More contrast is seen in first three letters  on  left than three letters on  right. 
The contrast is decreases from line to line. The size of  letters is 4.9 x 4.9 cm 
(2x2 inches). The highest contrast of 1 or 100% is seen on  letters on  left of  
top, and the lowest contrast, 0.006 or 0.6% is seen on  letters on  right of  
bottom. 49 
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The values of logarithmic contrast sensitivity (1/contrast)  were given 
on result paper.  Different sets of letters were present on  each side of  chart. 
A testing distance of 1 m is used and this indicates  a spatial frequency of 
about 1 cycle per degree (cpd) . The logarithmic contrast sensitivity value of  
last triplet of which at least 2 letters are correctly seen are marked as  result.  
Luminance of  test is  85 candelas/m2 (cd/m2) and accepted  is between 60 to 
120 cd/m249. 
VISUAL ASSESSMENT 
Because visual loss is the most common and serious complication of1° 
IIH, visual function should be assessed using kinetic (Goldmann) or static 
(Humphrey 24-2 or 30-2) perimetry and Snellen visual acuity testing. Fundus 
photography at the initial and subsequent evaluations is helpful for 
surveillance of these patients. The importance of repeated ophthalmic 
observations of best-corrected visual acuity, visual fields, and intraocular 
pressure, as well as careful examination for afferent pupil defects is essential. 
PERIMETRY 
Visual field defects  in  standard automated  perimetry  may be seen in 
upto 90% of patients, even when their visual acuity and colour vision are 
normal during early stages of papilledema. Visual field testing by automated 
perimetry  is  useful in identifying  optic nerve damage causing visual loss 
,especially in the early stages of the disease43. Quantitative perimetry by static 
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or kinetic perimetry is  currently used for assessing visual fields in 1° IIH. 
Motion perimetry can detect the visual field defects that are identified by the 
standard  automated perimetry  and also the defects which are missed by the 
standard perimetry. In motion perimetry, computer  generates  small circular 
regions of coherent motion perception targets all over  the central visual 
field78. 
In general, the field defects associated with 1° IIH are  related to disc, 
i.e., nerve fibre bundle, and analogous to glaucomatous field defects. The 
field defects include  enlarged blind spot, inferonasal constriction steps, 
arcuate defects, inferior altitudinal loss, and generalised constriction51. 
Enlargement of blind spot is seen in 30%, concentric constriction 
(29%) and complete blindness in 25% with rest of the defects including 
central & arcuate scotomas. 
In chronic papilledema, the inferonasal quadrant is most often affected. 
Dense paracentral scotomas may be present in Bjerrum area and may progress 
to form ring scotoma. The defects can be reversed if ICP is lowered before 
chronic papilledema develops. 
Kinetic Goldmann perimetry using Armaly – Drance testing strategy 
can detect field defects when ~30 % of the optic nerve fibres are lost51. Static 
perimetry using the Humphrey 24-2 or 30-2 algorithm is a more sensitive 
detector of visual –field loss than is Goldmann perimetry10. Automated visual 
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field is the testing strategy used by most ophthalmologists. Repeated 
measurements of blind spot size alone are neither adequate nor useful, 
because blind spot enlargement is largely refractive and similar blind spot 
enlargement can be seen in conditions unrelated to increased CSF pressure. 
Progression of visual field defect or occurrence of new field defects should be 
monitored with each visit52. 
RELATIVE AFFERENT PUPILLARY DEFECT: 
Asymmetries in afferent pupil function can alert a clinician to visual –
field loss that may not be recognised otherwise. The depth of the relative 
afferent papillary defect (RAPD) (measured in log units with neutral density 
filters) is roughly proportional to the area of visual field lost. Measurement of 
the RAPD provides objective evidence (but not an absolute measure) of 
asymmetric loss of visual field53. 
FUNDUS PHOTOGRAPHY: 
Fundus images give evidence of clinical course of papilledema and 
efficacy of the treatment regimen. Size that may herald new visual 
deterioration such as appearance of multiple infarcts in the disc or new 
optociliary collateral veins can be detected with sequential fundus 
photographs10.  
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INVESTIGATIONS 
IMAGING TECHNIQUES:54 
The usefulness of  neuroimaging studies in suspected cases of  1° IIH is two 
fold: 
             1.Before performing lumbar puncture and obtaining cerebrospinal 
fuid ,a neuro imaging study is the must  to exclude a condition that can put the 
patient at risk of herniation,  which can occur in cases of tumour producing 
hydrocephalus or mass effect. 
             2 .To  ensure  that  there is no secondary cause for raised  intracranial 
pressure.  
Computed tomography and MRI are the first line diagnostic imaging 
techniques in patients with 1° IIH. Slit like ventricles are not useful sign to 
discriminate between normal persons and those with 1° IIH. Empty sella 
turcica serves as indirect evidence that CSF pressure has been chronically 
elevated for at least six months. MRI coupled with MRV is the imaging of 
choice and  is the most effective way to screen for other possible causes of 
symptomatic hypertension such as tumour and hydrocephalus, sagittal or 
lateral sinus thrombosis54. 
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In 1° IIH, the findings of neuro-imaging studies(MRI with MRV) 
include: 
Ø Empty sella 
Ø  subarachnoid space that is seen around the optic nerve is 
dilated 
Ø Posterior sclera is flattened  at the lamina cribrosa 
Ø Normal or small slit like ventricles 
Ø Vertical tortuosity involving   the orbital portion of  optic 
nerve 
Ø The prelaminar optic nerve protrudes intraocularly 
Ø Enhancement involving the prelaminar portion of the  optic 
nerve (with gadolinium) 
Ø Stenosis can be noted in one or both transverse cerebral venous 
sinuses. 
Ø Enlarged optic nerve sheaths55. 
LABORATORY STUDIES: 
The lumbar puncture is done only after an intracranial lesion or mass 
has been ruled out by the neuroimaging studies to prevent the risk of 
herniation. Normal CSF pressure in adults is usually 200 mm H20 whereas in 
prepubertal children the value can < 200 mm H20. Increased ICP is suspected 
when the CSF is pressure is > 200 mm H20.  
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Lumbar puncture is mandatory for all patients suffering from 1° IIH. 
The diagnosis depends on demonstration of elevated CSF pressure >250 mm 
H2O, given the significance of this finding ,a normal pressure measurement 
on the first spinal tap demands a second spinal tap  in appropriate cases 
before1° IIH can be ruled out57. 
Several  CSF pressure recordings  or long term  CSF pressure 
monitoring may be needed due to normal fluctuation in the CSF pressure.  
Sometimes  normal obese women might  have a CSF pressure of more than 
250mm of H20. So, CSF  pressure  reading should  be correlated  with clinical 
findings before making  the diagnosis of 1° IIH58. 
 Accurate CSF pressure  reading is obtained especially when patient 
lies in a lateral decubitus position with his legs partially extended in a relaxed  
position. There are chances for the pressure to artifactually elevated while 
crying ,doing  Valsalva maneuver and also  with severe pain. 58 
CSF analysis has to  be done  to rule out inflammation, tumour cells 
and infection.CSF from patients with 1° IIH usually contains normal or low 
protein (<20mg/dl),normal glucose levels, normal cell count. Abnormal CSF 
contents mandate a meticulous search for other aetiologies of raised CSF 
pressure56. 
Some serological tests are to be performed when aetiology is unclear. 
These include antinuclear antibody testing, VDRL/RPR/FTA ABS testing, 
serum calcium if there is any evidence  of hypoparathyroidism since venous 
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sinus occlusion is one of the important diagnostic consideration, it is 
reasonable to do anticardiolipin antibodies, protein C and S , activated protein 
C resistance, antithrombin III levels56. 
ULTRASONOGRAPHY: 
The diameter of the optic nerve sheath is accurately measured by the 
standard A-scan orbital ultrasonography.40 
If there  is increased subarachnoid fluid surrounding the optic nerve 
,then the diameter of optic nerve increases in primary gaze and reduces by 
25% in eccentric gaze (30 degree test).This finding is diagnostic of 
papilledema if it is bilateral 40. 
But this noninvasive technique  needs excellent skills so that  the 
results can be reproduced.  This is the major drawback of this radio-imaging 
technique.40 
VISUAL EVOKED POTENTIAL 
 visual evoked potentials(VEP) is  used as screening tool  for detecting  
the injuries in the optic nerve. But in VEP , the central 10 degrees of  visual 
field only tested. Flash and pattern VEP provide disappointingly little 
information about impending visual loss in 1° IIH. Prolongation of VEP 
latency and central vision loss are the last manifestations of visual loss due to 
papilledema. By time the visual evoked potential is abnormal, visual acuity is 
defective and permanent serious visual loss has usual50. 
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MANAGEMENT 
Though idiopathic intracranial hypertension is diagnosed by a 
neurologist , further management and follow up of these patients also requires 
an ophthalmologist. All patients with suspected 1° IIH should undergo a 
complete neuro ophthalmic examination and visual fields by standard 
automated perimetry  at the time of presentation. The MRI and lumbar 
puncture, in that order, are  performed. 62 
TREATMENT: 
It depends upon factors such as 
· Headache and its severity 
·  degree of visual deterioration during  the time of diagnosis 
·  progression of  the  visual loss and its rate 
· presence of   underlying causes 
· factors associated with poor visual prognosis such as 
v High grade papilledema with macular edema 
v Venous sinus thrombosis 
v Systemic hypertension 
· pregnancy 
Primary goals of treatment 
1. To preserve vision 
2. To alleviate the symptoms 
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IIHTT (IDIOPATHIC INTRACRANIAL HYPERTENSION 
TREATMENT TRIAL): 
It is a multicenter, double blind , randomised ,placebo controlled study 
of acetazolamide in 165 1° IIH patients with mild visual loss(perimetric mean 
deviation of  -2 dB to -7 dB ).The trial concluded that there was a 
significantly better visual outcome ,significantly improved papilledema, 
quality of life measures and lower CSF pressures in subjects taking 
acetazolamide along with a low sodium diet program, in comparison to those 
taking placebo along with diet control program. So, acetazolamide in the 
maximally tolerated dosage along with diet control program is suggested for 
all patients with mild visual loss. Patients without visual loss with grade 1 or 
grade 2 papilledema can be managed with diet alone. They should be closely 
followed and if they worsen , acetazolamide can be added.  
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MEDICAL MANAGEMENT 
               It includes 
1. WEIGHT LOSS FOR OBESE PATIENTS: 
 Weight reduction is the must in all obese patients with 1° IIH.. Along with 
decreased food intake, sodium restriction must be advised  because of the 
presence of orthostatic edema and increased retention of sodium and water. 
Lowering caloric and sodium intake may be all that is therapeutically required 
for some asymptomatic patient. As little as 5-10% weight loss had resulted in 
reduced ICP with resolution of papilledema 59-61.Limiting Vit. A and tyramine 
in diet may be beneficial62, 63. Because dieting is difficult for many people, 
weight programs should be prescribed with kindness and support, not 
‘encouraged’ by threats of blindness. Patients should be sent for dietary 
instruction. weight reduction should be considered on long term basis and it is 
usually not employed as sole treatment modality in patients with acute visual 
loss62 . 
Vertical-banded gastroplasty and other bariatric operative 
procedures have been used with mixed success. One of the most important 
studies of 1° IIH showed universal relief of papilledema and a drop in CSF 
pressure after various surgical regimens used for obesity. This firmly 
establishes the importance of obesity as an etiologic factor in this condition. 
These bariatric surgical procedures have many complications, however, and 
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should not be taken lightly. The risk of intra operative hypotension and 
ischemic damage to the swollen optic nerve heads should not be 
disregarded64. 
2. DRUGS TO CONTROL INTRACRANIAL PRESSURE: 
(i)  Carbonic anhydrase inhibitors 
Acetazolamide is most frequently used. It acts by reducing the CSF 
production by decreased sodium ion transport across the choroidal plexus 
epithelium65. 
Dosage: 
The initial dose for adults is 250 mg QID (or) 500 mg BD. 66 
Side Effects: 
Fatigue, nausea, anorexia, tingling in the hands/feet and around the 
mouth, mild metabolic acidosis, renal stones, acute tubular necrosis, fatal 
hepatic dysfunction and aplastic anaemia   are the side effects of 
acetazolamide67. 
Contraindications: 
Patients allergic to sulfa based drugs, hepatic and renal disease, 
adreno-cortical insufficiency, severe pulmonary obstruction. 
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Precautions: 
Caution is required  in severe pulmonary disease and  in patients who 
take high dose of aspirin. 
Pregnancy: 
Fetal risk has been revealed in animal studies but not established in 
humans. 
(i)  Diuretics: 
Furosemide is commonly used diuretic. The reabsorption of sodium 
from the ascending limb of loop of henle is inhibited and they also have a 
weak carbonic anhydrase inhibitor action. Combining diuretics with other 
carbonic anhydrase inhibitors may produce hypokalemia and hence used with 
caution8. 
Dosage: 
  20-40 mg BD daily. It can be increased to a maximum of 80 mg 
BD with appropriate monitoring. 
(ii)  Corticosteroids: 
These are given when there is an inflammatory etiology for 1° IIH. 
Because of its significant adverse effects and rebound increase in ICP on 
withdrawal of steroids, it is used only in patients who have progressive visual 
loss requiring surgical treatment8. 
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3.MANAGEMENT OF HEADACHE: 
When headache is the only symptom of 1° IIH, treatment should 
be directed at its relief, preferably with standard headache remedies such as 
beta blockers, calcium channel blockers, and non steroidal anti-inflammatory 
drugs such as naproxen. since the long term use of NSAIDS can cause  
rebound headache, their use should be  only for few days to week.68  
   Tricyclic antidepressants, although helpful for chronic 
headache, also stimulate appetite, and there is clearly a relationship between 
obesity and 1° IIH68. 
TOPIRAMATE: 
   The recent addition of the anticonvulsant topiramate to the 
headache armamentarium provides weak carbonic anhydrase inhibition, 
headache relief and is an anorectic agent as well. The one drawback is the 
potential for developing acute angle closure glaucoma. Efficacy of topiramate 
is comparable to acetazolamide in the treatment of 1° IIH. Weight reduction 
as well as reduced CSF production is the possible mechanism of action69. 
OCTREOTIDE : 
Octreotide is a somatostatin analogue found to be effective for 
migraine and cluster headache. Though this effect may be mediated solely by 
reduction of ICP, additional mechanisms like inhibition of serotonin, 
bradykinin, prostaglandins, substance P, vaso-active intestinal peptides have 
been involved70.  
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REPEATED LUMBAR PUNCTURES: 
Frequent lumbar punctures can be used for relief of headache, but 
repeated spinal taps are painful, difficult to perform especially in obese 
patients. Occasionally, post lumbar puncture headache may develop. 
Repeated taps makes CSF to leak from multiple needle holes in the lumbar 
theca and simulate a lumbar peritoneal shunt. Spinal epidermoid tumors may 
be the end result of repeated lumbar punctures. So, this is not routinely done 
because of several drawbacks8. 
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SURGICAL MANAGEMENT 
SURGERY: 
Surgery is the treatment of choice in the following situations:  
· When there is  a new visual field defect development 
· Enlargement  is noted in the  prexisting field defect 
· When there is severe deterioration of visual parameters at the time 
presentation. 
· When there is a possibility of developing hypotension due to 
treatment of hypertension or renal dialysis. 
· Headache unresponsive to standard treatment. 
· When patient is not able  perform  visual field studies, 
· non-compliance to medical treatment and life style modifications 
by the patient. 
· Severe or rapid visual deterioration  during the time of diagnosis 
including relative afferent pupillary defect or  optic nerve 
dysfunction (malignant  IIH).8 
· Severe grade of  papilledema  associated with macular edema and  
exudates8. 
Mainly two procedures  are performed that includes  optic nerve 
sheath fenestration (or) CSF diversion procedures like lumbo-peritoneal (or) 
ventriculo-peritoneal shunt. 
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SURGICAL PROCEDURES: 
OPTIC NERVE SHEATH FENESTRATION: 
It is  done in patients who present with  severe or progressive visual 
loss. In this surgery, CSF pressure is reduced by creating windows or slits in 
the dura and arachnoid that surrounds the optic nerve ,so that the CSF is 
allowed to egress ,this in turn results in decrease of  CSF pressure and 
improvement in the severity of papilledema. Lateral orbitotomy approach has 
been used but the medial approach (transconjunctival and under the medial 
rectus) is less complicated and currently more popular. It is done preferably 
under general anaesthesia. The medial approach avoids the temporal posterior 
ciliary artery and so the submacular choroid blood supply is not 
compromised.71 
MECHANISM: 
1. Filtering effect reduces the local CSF pressure and this in turn  
improves the peripapillary circulation. 
2. Generalised decrease in intracranial pressure71. 
3. Scarring occurs in the region of  arachnoid after surgery and this  
protects the nerve head from raised CSF pressure72. 
COMPLICATIONS:   
· Temporary disinsertion of medial rectus leads to adduction deficit. 
· Damage to the short ciliary nerves leads to transient tonic pupil. 
·  Development of New visual field defect 
· Orbital hemorrhage 
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· Transient or protracted blindness 
·  Perforation of the globe72 
· Uncommon complications include  
         Occlusion of central retinal artery,  
                     Occlusion of branch retinal artery, 
                    Development of infarcts in the Choroidal  region, 71  
                   worsening optic neuropathy71. 
ADVANTAGES: 
· Shorter anesthesia 
· Shorter hospitalisation 
· Avoids complications of shunting procedures. 
OUTCOME: 
Improvement of disc swelling in the fellow eye and resolution of 
headache suggest that optic nerve sheath decompression acts a filtering 
procedure. Although, instantaneous decompression of the optic nerve is 
essentially guaranteed by this procedure, in long term 32% of the cases may 
experience deterioration following initial successful surgery. In these cases, 
lumbo-peritoneal shunting is preferred71. 
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LUMBO-PERITONEAL SHUNTING: 
Lumbo-peritoneal shunting is done most commonly  than ventriculo-
peritoneal shunting because difficulties arise while inserting VP shunts and 
the patency of  these shunts are also difficult to maintain the  72.  
Lumbo-peritoneal shunt is an effective surgical method for relieving 
papilledema and headache. Unfortunately, it has many complications and 
cannot be recommended for any patient who may require subsequent 
abdominal surgeries. Re-operation after lumbo-peritoneal shunt is almost the 
rule. Shunts require careful long term neurosurgical follow up because shunt 
failure can occur 5 or more years after placement with rapid and disastrous 
recurrence of papilledema72.  
The revision rate that may be required  for LP shunts is from 38%-
64%72. 
COMPLICATIONS: 
1. Shunt valve obstruction 
2. Over shunting 
3.  Migration of the catheter 
4. Abdominal pain 
5. Lumbar radiculopathy 
6. Infection 
7. Leakage of CSF 
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8. Shunt dependency 
9. Acquired Chiari malformation72. 
VENOUS SINUS STENTING: 
Stenosis of   transverse sinuses  can be seen in large number of 1° IIH 
patients73. This  leads  to obstruction in the venous outflow and  there occurs 
an increase in  intracranial venous pressure proximal to the area of stenosis 
and reduced CSF absorption via arachnoid granulations which raises the ICP. 
In these situation , endovascular stents can be used to reconstruct the venous 
lumen and it is  effective in reducing elevated ICP74. Since only fewer  
information is available about the  visual outcomes  in venous sinus stenting , 
more  clinical studies are needed  to establish the  safety and efficacy of this 
surgery over a long term period,for it to be used in 1° IIH patients refractory 
to standard treatment75.   
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FOLLOW UP 
The  follow up visit is  mainly decided by  
v Visual parameters  in the patient at the time of presentation 
v Underlying disease causing increased ICP 
v Patient’s  compliance  with regard to medical therapy 8 
Patients are asked to come for follow up every 3-4 weeks. Daily 
monitoring for a week is required in patient with  a significant visual function 
deterioration  or severe grade of  papilledema at the time of diagnosis, until  
some improvement and subsequent stability in their visual function is 
demonstrated.76 
Follow up is usually every 1-3 months at disease onset till there is an 
established   pattern in  the  progression or stability but in some patients with 
rapid progression close follow up is required.76 
 Whenever visual function is not stabilised, clinician should  refer  the 
patient for surgical treatment .  
Follow-up examinations should include the following: 
 best corrected visual acuity (both for distant and near vision), 
anterior segment examination including pupils and EOM.  
colour vision,  
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standard automated perimetry, 
 Fundus photography should be recorded. 8,76 
Kinetic perimetry can be done in  those who do not  do well on static 
perimetry. To monitor disc swelling, fundus photograph should be taken at 
presentation, then again once when the papilledema resolves. 8, 76 
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COMPLICATIONS 
The most dreaded complication of 1° IIH is  secondary optic atrophy  
that results from a long standing papilledema. 
It is characterised by the  following 
- presence of  constricted  peripheral visual fields, 
- worsened visual field defects,  
- a defective colour vision , development of RAPD, 
- In end stage disease, a drop in visual acuity. 
Occasionally, there are chances for a patient to  develop an acute loss 
of vision because of ischemic optic neuropathy or a retinal vascular occlusion 
associated with papilledema.76 
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VISUAL OUTCOME IN 1° IIH 
 In patients with 1° IIH, Visual prognosis is good and more 
encouraging  in patients who are  treated  timely and appropriately .  
 Medical management with acetazolamide and diet restriction with 
weight control  alone is sufficient for most patients with  who present with 
mild to moderate visual loss. Recurrences in this group are relatively 
infrequent.8 
Among those  patients with serious visual loss in whom surgery is 
needed, the residual  decreased visual acuity and field defects are present and 
this is more debilitating and recurrences are more frequent in these patients. 
Follow up in these patients should include semi- annual examinations for at 
least 2-3 years following surgery8. 
 
Recurrence rate of  8% to 37% is seen in  patients with 1° IIH  often 
years after diagnosis76 following recovery from initial presentation or after a 
long  period of stability. Weight  gain  is the independent factor which has 
been found to be associated  with  recurrence of the disease. 
Hence a long term follow up is mandatory in all patients with 1° IIH  
for years after  initial presentation. Medical management can also be needed 
on long term basis in these patients.  
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Malignant  IIH: 
 It is characterised by  rapid  and sudden onset of symptoms and visual 
deterioration with significant visual field loss,  visual acuity loss, very severe 
grade of  papilledema at  the time of presentation. Macular edema (or) 
Ophthalmoparesis may also be present. A progressive (or) malignant course 
requires rapid & aggressive treatment. Even surgical procedures are 
unsuccessful in preserving vision. Central venous sinus thrombosis is to be 
ruled out in all these patients.8 
IIH IN PREGNANCY: 
 Pregnant women with 1° IIH are diagnosed & treated similar to non 
pregnant women.  Most of the patients have  good visual prognosis and there 
is very little chance for permanent visual loss. Pregnancy is not 
contraindicated in those patients with previous history of 1° IIH .Majority of 
the patients may be managed with careful neuro-ophthalmic follow up. 
Acetazolamide may be used after 20 weeks of gestation.,  
Caloric restriction  and of use of thiazide diuretics and Tricyclic 
antidepressants are generally not advocated   during  pregnancy . If vision 
deteriorates, steroids may be used. ONSD (or) Lumbo-peritoneal shunting 
may be performed if needed, though there is theoretical risk of shunt 
malfunction from peritoneal catheter obstruction as the uterus enlarges. 1° IIH 
in postpartum period (or) following fetal loss should raise the suspicion of 
cerebral venous thrombosis.8 
56 
 
VISUAL OUTCOME OF 1° IIH IN MEN:   
Though the incidence rate of 1° IIH in men is low when compared to 
women, men have  two times more risk  of  severe visual deterioration  when 
compared to women in one or both eyes. Worse visual prognosis in men could 
be because of fewer nonvisual symptoms experienced  early in the course of 
the disease than women. The different symptom profiles between men and 
women could represent differences in the symptom expression or symptom 
thresholds between the sexes .So, men with 1° IIH should be followed up very 
closely regarding visual function.8 
Visual outcome of1° IIH in children: 
Though the incidence of 1° IIH is relatively rare in children, male: 
female ratio is 1:1 ,unlike in adults. When they reach the adolescence age 
group, 1° IIH  is  more commonly found in pubertal females.   Although the 
visual outcome in children is relatively benign when compared to adults , 
difficulties arise in diagnosing the disease (due to atypical clinical 
presentations),recording the opening CSF pressure, reliability of monitoring 
the visual parameters in children is doubtful .children usually do well on 
medical management itself and rarely CSF diversion procedures are required. 
The studies have shown a recurrence rate of 24%  and the recurrences are 
more common after 18 months from the diagnosis.8,76 
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                                                AIM OF THE STUDY 
To study the visual outcome in terms of visual acuity, visual field 
defects and fundus changes in patients with primary idiopathic intracranial 
hypertension at the time of diagnosis and after  3&6 months follow up. 
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MATERIALS AND METHODS 
PLACE:  GOVT.STANLEYMEDICALCOLLEGE                                                                                            
                 DEPARTMENT OF OPHTHALMOLOGY. 
PERIOD:   November 2014-september 2015 
STUDY DESIGN: prospective hospital based study. 
INCLUSION CRITERIA: 
Newly diagnosed patients with PRIMARY IDIOPATHIC 
INTRACRANIAL HYPERTENSION in the department of neurology 
,GOVT. STANLEY MEDICAL  COLLEGE. 
EXCLUSION CRITERIA: 
Patients with concurrent ocular illness or any other systemic diseases 
associated with visual loss and field defects were excluded from the study. 
Patients with recurrent episode of IIH 
Patients with secondary causes of IIH 
 
An  informed  consent was obtained from all patients who were 
included in the study. Detailed history regarding symptoms (headache, 
Diplopia, transient visual obscurations) and duration of symptoms were noted. 
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Specific history was taken to rule out secondary causes of IIH. History 
of medication use(tetracycline group of antibiotics, vitamin A, oral 
contraceptive pills, steroids, other antibiotics usage) were noted. 
 
History of recent weight gain was noted. The patient’s height and 
weight were recorded during each visit. 
 
A thorough ophthalmic examination that included measurement of  
Best corrected  visual acuity, 
Extraocular movements, 
Colour vision by Ishihara’s plates, 
Intraocular pressure measurement, 
Slit lamp examination  
            Fundus examination was done. 
Disc edema was graded and fundus photography was taken. Standard 
automated perimetry was conducted  in a 31.5 apostilb background. Any 
scotomas (other than the physiological blind spot) not eliminated  by  
refraction were tabulated .Constriction of visual fields was considered when 
isopters fell atleast 10 degree from where they were expected. 
Patients were counselled about the importance of weight loss and low 
sodium diet in the treatment of 1° IIH and started on tablet acetazolamide 500 
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mg in BD dosing. The side effects of acetazolamide was explained to the 
patients. The patients were asked to review after 2 weeks to note the response 
to treatment. Patients who responded poorly to medical 
management(progressive field loss, worsening  of visual acuity, no 
improvement in symptoms) have undergone surgical CSF diversion 
procedure(lumbo peritoneal shunt).Those  patients  who presented  at the time 
of diagnosis with poor visual parameters and those who had very high CSF 
pressures(>350 mm H20) have undergone lumboperitoneal  shunt  procedure 
at or before 2 weeks.  Subsequently they were asked to review at one month, 
three months and six months. With each visit patient underwent a thorough 
ophthalmic examination that included 
Best corrected visual acuity, 
Extra ocular movements, 
IOP measurement, 
Fundus photography, 
Automated perimetry. 
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RESULTS 
Statistical analysis was performed using SPSS version 16 and 
Microsoft excel 2007.P value <0.05 was considered significant. 
 
DATA ANALYSIS: 
The patients were divided into two groups- 
Group A-   patients with good visual outcome during the follow up 
period. 
Group B-  patients with minimal /no improvement/worsened visual 
outcome during the follow up period. 
Descriptive statistics was done for all data and were reported in terms 
of mean value and percentages. Suitable statistical tests of  comparison were 
done. Continuous variables were analysed with unpaired t test. Categorical 
variables were analysed with Fisher exact test and Mcnemars Chisquared test. 
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AGE: 
The number of patients included in the study is 35 patients. The age 
distribution of these patients is as follows: 
 
 
Age Distribution All % Group A % Group B % 
≤ 20 years 4 11.43 4 16.00 0 0.00 
21-30 years 27 77.14 20 80.00 7 70.00 
31-40 years 4 11.43 1 4.00 3 30.00 
Total 35 100 25 100 10 100 
 
Age Distribution All Group A Group B 
N 35 25 10 
Mean 26.80 26.00 28.80 
SD 4.55 4.75 3.43 
P value Unpaired t Test 0.0643 
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Gender  
  Of the 35 patients, 32 were females and 3 were males. 
 
Gender Distribution All % Group A % Group B % 
Male 3 8.57 1 4.00 2 20.00 
Female 32 91.43 24 96.00 8 80.00 
Total 35 100 25 100 10 100 
P value Fishers Exact Test 0.1902 
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WEIGHT GAIN: 
History of recent weight gain was present in 70% of the patients. 
Weight Gain
present
absent
 
Presenting symptoms: 
Symptoms Percentage of patients 
Headache 75% 
Tinnitus 55% 
Transient visualobscurations 45% 
Reduced visual acuity 40% 
Nausea and vomiting 25% 
Diplopia 10% 
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Visual Acuity 
On Presentation 
At the time of presentation, 
19 patients had visual acuity of 6/6. 
 Visual acuity was 6/9 - 6/12 in 6 patients. 
Visual acuity of 6/18 - 6/60 in 9 patients. 
<6/60 was present in 1 patient. 
19 19
6 6
9 9
1 1
0
2
4
6
8
10
12
14
16
18
20
All Group A Group B
6/6 6/9 -6/12 6/18 - 6/60 < 6/60
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On Presentation 
Visual Acuity 
All % Group A % Group B % 
6/6 19 54.29 19 76.00 0 0.00 
6/9 -6/12 
          
6 
17.14 6 24.00 0 0.00 
6/18 - 6/60 9 25.71 0 0.00 9 
90.0
0 
< 6/60 1 2.86 0 0.00 1 
10.0
0 
Total 35 100 25 100 10 100 
P value Fishers Exact Test 0.0000 
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Follow up at 3 months 
Vision was 6/6 in 22 patients 
Vision was 6/6 -6/9 in 3 patients. 
Patients with 6/18 to 6/60 at the time of diagnosis showed minimal or no 
improvement. 
 
Follow up at 3 
months Visual acuity All % Group A % Group B % 
6/6 22 62.86 22 
88.0
0 
0 0.00 
6/6 - 6/9 3 8.57 3 
12.0
0 
0 0.00 
6/18 - 6/60 9 25.71 0 0.00 9 90.00 
< 6/60 1 2.86 0 0.00 1 10.00 
Total 35 100 25 100 10 100 
P value Fishers Exact Test 0.0000 
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Followup at 6 months 
Vision of 6/6 was maintained in 22 patients. Vision of 6/6-6/9 was 
maintained in 3 patients. Patients with vision of 6/18-6/60 showed minimal or 
no improvement.2 patients worsened to vision of <6/60.  
 
 
 
 
 
 
Follow up at 6 months 
Visual Acuity 
All % 
Group 
A 
% 
Group 
B 
% 
6/6 22 62.86 22 88.00 0 0.00 
6/6 - 6/9 3 8.57 3 12.00 0 0.00 
6/18 - 6/60 8 22.86 0 0.00 8 80.00 
< 6/60 2 5.71 0 0.00 2 20.00 
Total 35 100 25 100 10 100 
P value Fishers Exact Test 0.0000 
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On Presentation Vs Follow up at 3 & 6 Months  
19
22 22
3 3
6
9 9 8
1 1 2
0
5
10
15
20
25
On Presentation Followup at 3 months Followup at 6 months
6/6 6/6 - 6/9 6/9 - 6/12 6/18 - 6/60 < 6/60
 
Visual 
Acuity 
On 
Presentation 
Follow up at 3 
months 
Follow up at 6 
months 
6/6 19 22 22 
6/6 - 6/9 0 3 3 
6/9 - 6/12 6 0 0 
6/18 - 6/60 9 9 8 
< 6/60 1 1 2 
P value Mcnemars Chi Squared Test 0.0000 
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FUNDUS 
On Presentation 
  Early papilledema seen in 22 patients. Established papilledema seen in 
12 patients. Chronic papilledema was seen in 1 patient. 
 
On Presentation Fundus All % Group A % Group B % 
Early Papilledema 22 62.86 22 88.00 0 0.00 
Established Papilledema 12 34.29 3 12.00 9 90.00 
Chronic Papilledema 1 2.86 0 0.00 1 10.00 
Atrophic Papilledema 0 0.00 0 0.00 0 0.00 
Total 35 100 25 100 10 100 
P value Fishers Exact Test 0.0000 
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FOLLOW UP AT 3 MONTHS 
22 patients with early papilledema improved to normal fundus . 
12 patients with established papilledema showed reduction in 
papilledema. 
1 patient with chronic papilledema  showed no improvement. 
22 22
12
3
9
1 1
0
5
10
15
20
25
All Group A Group B
Normal Papilledema Reducing
Early Papilledema Established Papilledema
Chronic Papilledema Atrophic Papilledema
 
Follow up at 3 months Fundus All % Group A % Group B % 
Normal 22 62.86 22 88.00 0 0.00 
Papilledema Reducing 12 34.29 3 12.00 9 90.00 
Early Papilledema 0 0.00 0 0.00 0 0.00 
Established Papilledema 0 0.00 0 0.00 0 0.00 
Chronic Papilledema 1 2.86 0 0.00 1 10.00 
Atrophic Papilledema 0 0.00 0 0.00 0 0.00 
Total 35 100 25 100 10 100 
P value Fishers Exact Test 0.0000 
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FOLLOWUP AT 6 MONTHS: 
 25 patients maintained normal fundus. 
8 patients showed reducing papilledema. 
2 patients showed chronic papilledema. 
25 25
8 8
2 2
0
5
10
15
20
25
30
All Group A Group B
Normal Papilledema Reducing
Early Papilledema Established Papilledema
Chronic Papilledema Atrophic Papilledema
 
Follow up at 6 months Fundus All % Group A % Group B % 
Normal 25 71.42 25 100 0 0.00 
Papilledema Reducing 8 22.85 0 0.00 8 80.00 
Early Papilledema 0 0.00 0 0.00 0 0.00 
Established Papilledema 0 0.00 0 0.00 0 0.00 
Chronic Papilledema 2 5.71 0 0.00 2 20.00 
Atrophic Papilledema 0 0.00 0 0.00 0 0.00 
Total 35 100 25 100 10 100 
P value Fishers Exact Test 0.0000 
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On Presentation Vs Follow up at 3 & 6 Months  
 
Fundus 
On 
Presentation 
Follow up at 3 
months 
Follow up at 6 
months 
Normal 0 22 25 
Papilledema 
Reducing 
0 12 8 
Early Papilledema 22 0 0 
Established 
Papilledema 
12 0 0 
Chronic 
Papilledema 
1 1 2 
Atrophic 
Papilledema 
0 0 0 
P value Mcnemars Chi Squared Test 0.0000 
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VISUAL FIELDS 
On Presentation 
 
On Presentation Visual 
Fields 
All % 
Group 
A 
% 
Group 
B 
% 
Normal 12 34.29 12 48.00 0 0.00 
Enlarged Blind Spot 20 57.14 13 52.00 7 70.00 
Generalized Reduced 
Sensitivity 
2 5.71 0 0.00 2 20.00 
Enlarged blind spot + 
Arcuate Scotoma 
1 2.86 0 0.00 1 10.00 
Total 35 100 25 100 10 100 
P value Fishers Exact Test 0.0000 
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FOLLOW UP AT 3 MONTHS 
 
Follow up at 3 months Visual 
Fields 
All % Group A % Group B % 
Normal 25 71.43 25 
100.0
0 
0 0.00 
Enlarged Blind Spot 0 0.00 0 0.00 0 0.00 
Generalised Reduced 
Sensitivity 
8 22.86 0 0.00 8 80.00 
Enlarged blind spot + 
Arcuate Scotoma 
0 0.00 0 0.00 0 0.00 
Constricted fields 2 5.71 0 0.00 2 20.00 
Total 35 100 25 100 10 100 
P value Fishers Exact Test 0.0000 
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Follow up at 6 months 
 
Follow up at 6 months 
Visual Fields 
All % 
Group 
A 
% 
Group 
B 
% 
Normal 25 71.43 25 100.00 0 0.00 
Enlarged Blind Spot 0 0.00 0 0.00 0 0.00 
Generalised Reduced 
Sensitivity 
8 22.86 0 0.00 8 80.00 
Enlarged blind spot + 
Arcuate Scotoma 
0 0.00 0 0.00 0 0.00 
Constricted fields 2 5.71 0 0.00 2 20.00 
Total 35 100 25 100 10 100 
P value Fishers Exact Test 0.0000 
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On Presentation Vs Follow up at 3 & 6 Months 
 
Visual Fields 
On 
Presentation 
Follow up at 3 
months 
Follow up at 6 
months 
Normal 12 25 25 
Enlarged Blind Spot 20 0 0 
Generalized Reduced 
Sensitivity 
2 8 8 
Enlarged blind spot + 
Arcuate Scotoma 
1 0 0 
Constricted fields 0 2 2 
P value Mcnemars Chi Squared Test 0.0000 
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Mode of Treatment 
 
 
Mode of 
Treatment 
All % 
Group  
A 
% 
Group 
B 
% 
Medical 27 77.14 25 100.00 2 20.00 
Medical +Surgical 8 22.86 0 0.00 8 80.00 
Total 35 100 25 100 10 100 
P value Fishers Exact Test 0.0000 
 
 
 
                                                    
 
 
MRI BRAIN SHOWING WIDENED 
PERIOPTIC SPACE IN 1° IIH 
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RESULTS 
 Of the 35 patients included in our study, 32 were females and 3 were 
male patients. The mean age of these patients was 26.80± 4.55years. 70% of 
the patients included in our study had positive history of recent weight gain. 
Of the presenting complaints, headache was the most common symptom. 
Other symptoms included pulsatile tinnitus, transient visual obscurations, 
blurring of vision, diplopia, nausea and vomiting. The average duration of 
symptoms was 6 months. Opening CSF pressure was 250-350 mm H20 in 32 
patients. Three patients had  >350 mm H20. Most common neuroimaging 
findings included  empty sella and prominent perioptic CSF spaces.  
Based upon the visual outcome in these 35 patients from the time of 
diagnosis till the follow up period of 6 months, they were divided into Group 
A and Group B.  
GROUP A: 
At the time of presentation, 19 patients had Snellen’s visual acuity of 
6/6 and six patients had visual acuity of 6/9 - 6/12. In these 25 patients, 22 
patients had early papilledema and three  patients had established 
papilledema. Visual field showed normal or minimal changes in these 25 
patients. When these patients were followed up at 3 months, 22 patients 
maintained their visual acuity of 6/6 and  three  patients improved to 6/6 – 
6/9. Early papilledema improved to normal fundus in 22 patients and three  
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patients had reduction in their established papilledema. All 25 patients had 
normal visual fields at the end of 3 months. At the end of 6 months, visual 
acuity of 6/6 was maintained in 22 patients and visual acuity between 6/6 – 
6/9 was maintained in three patients. Normal visual fields were present in all 
25 patients. These 25 patients had good visual outcome during the follow up 
period in comparison to Group B patients with significant P value (<0.05). In 
these 25 patients, only medical management was required during the follow- 
up period.    
GROUP B: 
At the time of presentation, nine  patients had vision between 6/18 – 
6/60 with established papilledema. One patient had vision < 6/60 with chronic 
papilledema with significant field changes.  
Of these 10 patients,  surgery was required  at the time of diagnosis in 
addition to medical treatment  due  to poor visual parameters  in 2 patients 
and  very high CSF pressure of  >350 mm H20  in three patients. 
  Three  patients  required  surgery around  4 weeks   due  to  no 
improvement/ progression  in visual  and non visual symptoms.  
At the end of 3 month and 6 month follow up period,  2 patients who 
underwent surgery  due to poor visual parameters at the time of diagnosis  
worsened inspite of surgical management. Remaining  6 patients  who 
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underwent surgery showed only  minimal  improvement but there was no 
worsening  during the follow up period in these patients.  
Remaining  2 patients on medical management showed minimal 
improvement  but  no progression of the disease was noted. 
In our study, out of 35 patients, 25 patients showed good improvement 
in the visual outcome during the follow up period. These 25 patients account 
for 72% of the patients included in our  study. In the remaining 10 patients, 8 
patients (23%) showed minimal  improvement and 2 patients (5%) worsened 
at the end of follow up period irrespective of the treatment given. The visual 
parameters at the time of  diagnosis were  relatively good in group A patients 
when compared to  group B patients with a significant P value of <0.05. 
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DISCUSSION 
The visual outcome in patients with Primary Idiopathic Intracranial 
Hypertension, who are treated appropriately early in the course of disease 
with careful monitoring of visual functions, has showed encouraging results. 
This can prevent the patients from ending up in irreversible loss of vision due 
to optic atrophy. Some patients tend to have a protracted course that lasts for 
years and in this period, they may be asymptomatic with chronic papilledema 
or have symptoms that need medical treatment  to decrease their ICP. 
All these patients of 1° IIH have to be closely followed up over a long 
term period, with their visual functions being carefully monitored. This 
regular monitoring prevents visual deterioration with timely intervention. One 
of the important factors that is linked with delayed relapse is weight gain and 
hence each and every patient with 1° IIH have to be counselled regarding 
weight reduction and diet control on a long term basis. 
In our study, out of 35 patients, male: female ratio was 1:10 which is 
comparable to the study conducted by Durcan FJ et al which showed a male: 
female ratio of 1: 9. 
Out of 35 patients included in our study, 25 patients (72%) showed 
good improvement in visual acuity, visual fields and fundus changes during 
the follow up period. These 25 patients had relatively good visual acuity, 
normal or minimal field changes and less severe grade of papilledema at the 
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time of presentation. 8 patients (23%) showed minimal or no improvement in 
the visual outcome during the follow up period. 2 patients (5%) showed 
worsening during the follow up period. This was comparable to the study 
conducted by Rowe FJ, Sarkies NJ et al on the assessment of visual function 
in primary Idiopathic Intracranial Hypertension: a prospective study.  
Of the 72% of patients who showed good visual outcome during the 
follow up period, the relatively good visual function (relatively good visual 
acuity, normal/minimal field changes and minimal fundus changes) was 
present at the time of diagnosis with significant P value of <0.05. 
The follow up period in our  study was only till 6 months. But, Primary 
Idiopathic Intracranial Hypertension is a progressive and chronic disease, with 
a relapse rate of 8% - 38%. So long term follow up with careful monitoring of 
visual functions is needed in all patients with 1° IIH to exactly analyse the 
risk factors associated with poor visual outcome.  
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CONCLUSION 
Visual outcome in patients with Primary Idiopathic Intracranial  
Hypertension depends on several factors , the important factors  being visual 
parameters (Visual Acuity, visual field defects and severity of papilledema) at 
the time of  clinical presentation and the duration  between  presentation and 
onset of treatment ,either medical or surgical. 
In our study, regarding the visual functions(including  Snellen’s  visual 
acuity, visual fields and fundus findings),patients who presented early  with  
much less  visual deterioration  recovered  better  than  who presented with  
significant visual deterioration,  irrespective of  the  surgical or medical 
intervention .  Patients with much less visual deterioration  at presentation  
showed  good improvement  with medical management itself in our study.  
The most common symptom in our study was headache. So all patients 
with headache should be evaluated for primary idiopathic Intracranial  
Hypertension and appropriate treatment should be initialized earlier to prevent 
severe visual loss in primary idiopathic Intracranial  Hypertension. Hence 
from our study, we conclude that  the earlier the treatment is started (either 
medical or surgical),the better the visual prognosis would be. 
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PROFORMA 
Name: 
Age/Sex: 
I.P.No.: 
Date: 
Weight: 
Height: 
BMI: 
HISTORY: 
Presenting symptoms: Headache/Nausea/Vomiting/Transient Visual  
    obscuration/Blurring of vision/Diplopia/Tinnitus/Others: 
Duration: 
H/o. Recent weight gain 
H/o. Prior medications 
H/o. Systemic illness 
GENERAL EXAMINATION: 
Vitals: Temperature/Pulse rate/Blood Pressure 
Anemia/Icterus 
CVS 
RS 
P/A 
Complete CNS Examination 
 
OPHTHALMIC EXAMINATION: RIGHT EYE LEFT EYE 
v Visual Acuity (Unaided) 
                       (BCVA) 
v Eyelids and lashes 
v Extra ocular movements 
v SLIT LAMP EXAMINATION: 
· Conjunctiva 
· Cornea 
· Anterior chamber 
· Iris 
· Pupil 
· Lens 
· IOP (Applanation Tonometry) 
 
v Fundus Examination 
v Colour Vision 
v Visual Fields by Automated Perimetry 
v CT/MRI Brain 
v CSF Pressure 
 
DIAGNOSIS: 
 
 
TREATMENT GIVEN: 
 
3 MONTHS & 6 MONTHS FOLLOW UP 
Date 
Weight 
Visual Acuity (BCVA) 
Anterior Segment 
Pupils 
Extra ocular Movements 
Fundus 
Colour Vision 
Automated Perimetry 
 
 
 
 
 
 
 
 
RE LE RE LE RE LE RE LE RE LE RE LE RE LE RE LE RE LE
1 Veda 29 F 6/6 6/6 Early Papilledema Early Papilledema Enlarged blind spot Enlarged blind spot Medical 6/6 6/6 Normal Normal Normal Normal 6/6 6/6 Normal Normal Normal Normal
2 Kasthuri 30 F 6/6 6/6 Early Papilledema Early Papilledema Normal Normal Medical 6/6 6/6 Normal Normal Normal Normal 6/6 6/6 Normal Normal Normal Normal
3 Revathi 21 F 6/12 6/9
Established 
Papilledema
Established 
Papilledema Enlarged blind spot Enlarged blind spot Medical 6/9 6/6
Papilledema 
Reducing
Papilledema 
Reducing Normal Normal 6/9 6/6 Normal Normal Normal Normal
4 Vijayalakshmi 36 F 6/6 6/6 Early Papilledema Early Papilledema Normal Normal Medical 6/6 6/6 Normal Normal Normal Normal 6/6 6/6 Normal Normal Normal Normal
5 Kanniyammal 31 F 6/60 p 6/60
Established 
Papilledema
Established 
Papilledema Enlarged blind spot Enlarged blind spot 
Medical + 
Surgical 6/60 6/60
Chronic 
Papilledema
Chronic 
Papilledema
Constricted 
fields
Constricted 
fields 5/60 6/60
chronic 
papilledema
chronic 
papilledema
Constricted 
fields Constricted fields
6 Santhanalakshmi 29 F 6/9 6/12
Established 
Papilledema
Established 
Papilledema Enlarged blind spot Enlarged blind spot Medical 6/9 6/9
Papilledema 
Reducing
Papilledema 
Reducing Normal Normal 6/6 6/9 Normal Normal Normal Normal
7 Logeswari 27 F 6/6 6/6 Early Papilledema Early Papilledema Enlarged blind spot Enlarged blind spot Medical 6/6 6/6 Normal Normal Normal Normal 6/6 6/6 Normal Normal Normal Normal
8 Bharathi 21 F 6/6 6/6 Early Papilledema Early Papilledema Enlarged blind spot Enlarged blind spot Medical 6/6 6/6 Normal Normal Normal Normal 6/6 6/6 Normal Normal Normal Normal
9 Sangeetha 23 F 6/6 6/6 Early Papilledema Early Papilledema Enlarged blind spot Enlarged blind spot Medical 6/6 6/6 Normal Normal Normal Normal 6/6 6/6 Normal Normal Normal Normal
10 Esther 24 F 6/6 6/6 Early Papilledema Early Papilledema Enlarged blind spot Enlarged blind spot Medical 6/6 6/6 Normal Normal Normal Normal 6/6 6/6 Normal Normal Normal Normal
11 Manimegalai 18 F 6/6 6/6 Early Papilledema Early Papilledema Enlarged blind spot Enlarged blind spot Medical 6/6 6/6 Normal Normal Normal Normal 6/6 6/6 Normal Normal Normal Normal
12 Sonia 20 F 6/6 6/6 Early Papilledema Early Papilledema Enlarged blind spot Enlarged blind spot Medical 6/6 6/6 Normal Normal Normal Normal 6/6 6/6 Normal Normal Normal Normal
13 Jayalakshmi 38 F 6/24 6/36 Established 
Papilledema
Established 
Papilledema
Enlarged blind spot Enlarged blind spot Medical + 
Surgical
6/18 6/24 Papilledema 
Reducing
Papilledema 
Reducing
Generalised 
Reduced 
Sensitivity
Generalised 
Reduced 
Sensitivity
6/18 6/24 papilledema 
reducing
papilledema 
reducing
Generalised 
Reduced 
Sensitivity
Generalised 
Reduced 
Sensitivity
14 Meena 28 F 6/36 6/24 Established 
Papilledema
Established 
Papilledema
Enlarged blind spot Enlarged blind spot Medical + 
Surgical
6/24 6/18 Papilledema 
Reducing
Papilledema 
Reducing
Generalised 
Reduced 
Sensitivity
Generalised 
Reduced 
Sensitivity
6/18 6/18 papilledema 
reducing
papilledema 
reducing
Generalised 
Reduced 
Sensitivity
Generalised 
Reduced 
Sensitivity
15 Karthiga 26 F 6/6 6/6 Early Papilledema Early Papilledema Normal Normal Medical 6/6 6/6 Normal Normal Normal Normal 6/6 6/6 Normal Normal Normal Normal
16 Prakash 30 M 6/6 6/6 Early Papilledema Early Papilledema Normal Normal Medical 6/6 6/6 Normal Normal Normal Normal 6/6 6/6 Normal Normal Normal Normal
17 Pramila 19 F 6/9 6/12
Established 
Papilledema
Established 
Papilledema Enlarged blind spot Enlarged blind spot Medical 6/9 6/9
Papilledema 
Reducing
Papilledema 
Reducing Normal Normal 6/6 6/9 Normal Normal Normal Normal
18 Valli 28 F 6/6 6/6 Early Papilledema Early Papilledema Normal Normal Medical 6/6 6/6 Normal Normal Normal Normal 6/6 6/6 Normal Normal Normal Normal
19 Pavithra 30 F 6/6 6/6 Early Papilledema Early Papilledema Enlarged blind spot Enlarged blind spot Medical 6/6 6/6 Normal Normal Normal Normal 6/6 6/6 Normal Normal Normal Normal
20 Kalaiselvi 23 F 6/6 6/6 Early Papilledema Early Papilledema Normal Normal Medical 6/6 6/6 Normal Normal Normal Normal 6/6 6/6 Normal Normal Normal Normal
21 Vimala 18 F 6/6 6/6 Early Papilledema Early Papilledema Normal Normal Medical 6/6 6/6 Normal Normal Normal Normal 6/6 6/6 Normal Normal Normal Normal
22 Rasia 32 F 5/60 6/36
Chronic 
Papilledema
Established 
Papilledema constricted fields
Generalised 
Reduced 
Sensitivity
Medical + 
Surgical 5/60 6/36
chronic 
papilledema
Chronic 
Papilledema
Constricted 
fields
Constricted 
fields 4/60 5/60
chronic 
papilledema
chronic 
papilledema
Constricted 
fields Constricted fields
23 Bhavani 30 F 6/6 6/6 Early Papilledema Early Papilledema Normal Normal Medical 6/6 6/6 Normal Normal Normal Normal 6/6 6/6 Normal Normal Normal Normal
24 Latha 36 F 6/36 6/36
Established 
Papilledema
Established 
Papilledema Enlarged blind spot Enlarged blind spot 
Medical + 
Surgical 6/24 6/24
Papilledema 
Reducing
Papilledema 
Reducing
Generalised 
Reduced 
Sensitivity
Generalised 
Reduced 
Sensitivity
6/18 p 6/18 p
papilledema 
reducing
papilledema 
reducing
Generalised 
Reduced 
Sensitivity
Generalised 
Reduced 
Sensitivity
Fundus Sl
. N
o
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tie
nt
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e
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ge Se
x
At Presentation
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e 
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t
Visual Fields
Followup at 3 months Followup at 6 months
Vision Fundus Visual Fields Vision Fundus Visual Fields Vision 
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Followup at 3 months Followup at 6 months
Vision Fundus Visual Fields Vision Fundus Visual Fields Vision 
25 Meena 45 F 6/36 6/24
Established 
Papilledema
Established 
Papilledema Enlarged blind spot Enlarged blind spot 
Medical + 
Surgical 6/24 6/24
Papilledema 
Reducing
Papilledema 
Reducing
Generalised 
Reduced 
Sensitivity
Generalised 
Reduced 
Sensitivity
6/18 6/18
papilledema 
reducing
papilledema 
reducing
Generalised 
Reduced 
Sensitivity
Generalised 
Reduced 
Sensitivity
26 Jayalakshmi 29 F 6/6 6/6 Early Papilledema Early Papilledema Normal Normal Medical 6/6 6/6 Normal Normal Normal Normal 6/6 6/6 Normal Normal Normal Normal
27 Kothandaraman 36 M 6/60 6/36
Established 
Papilledema
Established 
Papilledema
Generalised 
Reduced 
Sensitivity
Generalised 
Reduced 
Sensitivity
Medical + 
Surgical 6/36 6/24
Papilledema 
Reducing
Papilledema 
Reducing
Generalised 
Reduced 
Sensitivity
Generalised 
Reduced 
Sensitivity
6/24 6/24
papilledema 
reducing
papilledema 
reducing
Generalised 
Reduced 
Sensitivity
Generalised 
Reduced 
Sensitivity
28 Kanchana 30 F 6/6 6/6 Early Papilledema Early Papilledema Normal Normal Medical 6/6 6/6 Normal Normal Normal Normal 6/6 6/6 Normal Normal Normal Normal
29 Shobana 22 F 6/9 6/6 Early Papilledema Early Papilledema Normal Normal Medical 6/6 6/6 Normal Normal Normal Normal 6/6 6/6 Normal Normal Normal Normal
30 Gowthami 28 F 6/6 6/6 Early Papilledema Early Papilledema Normal Normal Medical 6/6 6/6 Normal Normal Normal Normal 6/6 6/6 Normal Normal Normal Normal
31 Anjalai 25 F 6/24 6/24 Established 
Papilledema
Established 
Papilledema
Enlarged blind spot Enlarged blind spot Medical 6/18 6/18 Papilledema 
Reducing
Papilledema 
Reducing
Generalised 
Reduced 
Sensitivity
Generalised 
Reduced 
Sensitivity
6/18 6/12 papilledema 
reducing
papilledema 
reducing
Generalised 
Reduced 
Sensitivity
Generalised 
Reduced 
Sensitivity
32 Vanathi 30 F 6/9 6/9 Early Papilledema Early Papilledema Enlarged blind spot Enlarged blind spot Medical 6/6 6/6 Normal Normal Normal Normal 6/6 6/6 Normal Normal Normal Normal
33 Puneetha 28 F 6/24 6/24 Established 
Papilledema
Established 
Papilledema
Enlarged blind spot Enlarged blind spot Medical 6/18 6/18 Papilledema 
Reducing
Papilledema 
Reducing
Generalised 
Reduced 
Sensitivity
Generalised 
Reduced 
Sensitivity
6/18 6/12 papilledema 
reducing
papilledema 
reducing
Generalised 
Reduced 
Sensitivity
Generalised 
Reduced 
Sensitivity
34 Sekar 39 M 6/36 6/24 Established 
Papilledema
Established 
Papilledema
Enlarged blind spot 
+ Arcuate 
Scotoma
Enlarged blind spot 
+ Arcuate 
Scotoma
Medical + 
Surgical
6/24 6/18 Papilledema 
Reducing
Papilledema 
Reducing
Generalised 
Reduced 
Sensitivity
Generalised 
Reduced 
Sensitivity
6/18 6/18 papilledema 
reducing
papilledema 
reducing
Generalised 
Reduced 
Sensitivity
Generalised 
Reduced 
Sensitivity
35 Sasirekha 29 F 6/9 6/9 Early Papilledema Early Papilledema Enlarged blind spot Enlarged blind spot Medical 6/6 6/6 Normal Normal Normal Normal 6/6 6/6 Normal Normal Normal Normal
ABBREVIATIONS 
1o IIH  -  Primary Idiopathic Intracranial Hypertension 
ICP  -  Intracranial Pressure 
CSF  - Cerebrospinal Fluid 
TVO  - Transient Visual Obscurations 
ONSD - Optic Nerve Sheath Decompression 
IOP  - Intra Ocular Pressure 
OCT  -  Optical Coherence Tomography 
RNFL  - Retinal Nerve Fibre Layer 
IIHTT - Idiopathic Intracranial Hypertension  
Treatment Trial 
 
 
  
 
 
 
 
  
 
